1
|
Zhu W, Zhang Y, Zhou Q, Zhen C, Huang H, Liu X. Identification and Comprehensive Analysis of circRNA-miRNA-mRNA Regulatory Networks in A2780 Cells Treated with Resveratrol. Genes (Basel) 2024; 15:965. [PMID: 39062744 PMCID: PMC11276136 DOI: 10.3390/genes15070965] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2024] [Revised: 07/17/2024] [Accepted: 07/18/2024] [Indexed: 07/28/2024] Open
Abstract
Ovarian cancer (OC) is one of the most commonplace gynecological malignancies. This study explored the effects of resveratrol (RES) on OC cell proliferation and apoptosis. Proliferation activity was measured for A2780 cells treated with RES for 24 h and 48 h at concentrations of 0, 10, 25, 50, 75, 100, 150, 200, and 300 μM. RNA sequencing (RNA-seq) was performed to analyze the circular RNA (circRNA), microRNA (miRNA), and messenger RNA (mRNA) expression spectrum. The differentially expressed genes included 460 circRNAs, 1988 miRNAs, and 1671 mRNAs, and they were subjected to analyses including Gene Ontology, the Kyoto Encyclopedia of Genes and Genomes (KEGG), and Reactome enrichment. We selected signaling pathways enriched in the cell processes by mRNA KEGG, comprehensively analyzed the circRNA-miRNA-mRNA regulatory network, and verified several miRNAs expressed in the regulatory network diagram using the quantitative real-time polymerase chain reaction. The data showed that the cell proliferation of A2780 cells treated with RES for 24 h or 48 h decreased with increasing concentrations of RES. The circRNA-miRNA-mRNA regulatory network that we constructed provides new insights into the ability of RES to inhibit cell proliferation and promote apoptosis in A2780 cells.
Collapse
Affiliation(s)
- Weihua Zhu
- Department of Basic Medical Sciences, Clinical College of Anhui Medical University, Hefei 230031, China
| | - Yuanting Zhang
- Department of Basic Medical Sciences, Clinical College of Anhui Medical University, Hefei 230031, China
| | - Qianqian Zhou
- Department of Basic Medical Sciences, Clinical College of Anhui Medical University, Hefei 230031, China
| | - Cheng Zhen
- Department of Basic Medical Sciences, Clinical College of Anhui Medical University, Hefei 230031, China
| | - Herong Huang
- Department of Basic Medical Sciences, Clinical College of Anhui Medical University, Hefei 230031, China
| | - Xiaoying Liu
- School of Life Sciences, Anhui Medical University, Hefei 230032, China
| |
Collapse
|
2
|
Fan YL, Jin JX, Zhu J, Ruan HB, Huang JQ. Extracellular vesicles of Bifidobacterium longum reverse the acquired carboplatin resistance in ovarian cancer cells via p53 phosphorylation on Ser15. Kaohsiung J Med Sci 2024; 40:530-541. [PMID: 38647095 DOI: 10.1002/kjm2.12837] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2024] [Revised: 04/09/2024] [Accepted: 04/10/2024] [Indexed: 04/25/2024] Open
Abstract
We previously found that the relative abundance of Bifidobacterium was increased after chemotherapy; however, the role of Bifidobacterium longum in chemotherapeutic drug resistance in ovarian cancer (OVC) remains unclear. This study aimed to understand the potential effects and mechanism of B. longum extracellular vesicles (B. longum-EVs) on carboplatin (CBP) resistance in OVC. Eight normal and 11 ovarian tissues were collected and the expression of B. longum genomic DNA and its association with acquired CBP resistance in OVC patients was determined. After isolating EVs by ultracentrifugation from B. longum (ATCC 15707), CBP-resistant A2780 cells were treated with PBS, CBP, B. longum-EVs, or CBP + B. longum-EVs, and subsequently analyzed by CCK-8, Edu staining, Annexin V/PI double staining, wound healing, and Transwell assays to detect cell viability, proliferation, apoptosis, migration, and invasion, respectively. MRP1, ATP7A, ATP7B, and p53 expression as well as p53 phosphorylation were measured by western blot analysis. S15A mutation of p53 was assessed to examine the potential role of p53 Ser15 phosphorylation in CBP-resistant OVC. B. longum levels were elevated and positively associated with CBP resistance in OVC patients. Only high concentrations of B. longum-EVs attenuated A2780 cell proliferation, apoptosis, migration, and invasion. B. longum-EVs exposure significantly enhanced the sensitivity of CBP-resistant A2780 cells to CBP and decreased the expression of drug resistance-related proteins. The effect of B. longum-EVs on reversing CBP resistance was completely inhibited by S15A mutation of p53. B. longum-EVs enhanced the sensitivity of OVC cells to CBP through p53 phosphorylation on Ser15.
Collapse
Affiliation(s)
- Yun-Long Fan
- Departments of Gynaecology and Obstetrics, The First People's Hospital of Wenling, Wenling, China
| | - Jia-Xi Jin
- Departments of Gynaecology and Obstetrics, The First People's Hospital of Wenling, Wenling, China
| | - Jun Zhu
- Departments of Gynaecology and Obstetrics, The First People's Hospital of Wenling, Wenling, China
| | - Hai-Bo Ruan
- Departments of Gynaecology and Obstetrics, The First People's Hospital of Wenling, Wenling, China
| | - Jin-Qun Huang
- Departments of Gynaecology and Obstetrics, The First People's Hospital of Wenling, Wenling, China
| |
Collapse
|
3
|
Kar A, Agarwal S, Singh A, Bajaj A, Dasgupta U. Insights into molecular mechanisms of chemotherapy resistance in cancer. Transl Oncol 2024; 42:101901. [PMID: 38341963 PMCID: PMC10867449 DOI: 10.1016/j.tranon.2024.101901] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2023] [Revised: 01/15/2024] [Accepted: 02/01/2024] [Indexed: 02/13/2024] Open
Abstract
Cancer heterogeneity poses a significant hurdle to the successful treatment of the disease, and is being influenced by genetic inheritance, cellular and tissue biology, disease development, and response to therapy. While chemotherapeutic drugs have demonstrated effectiveness, their efficacy is impeded by challenges such as presence of resilient cancer stem cells, absence of specific biomarkers, and development of drug resistance. Often chemotherapy leads to a myriad of epigenetic, transcriptional and post-transcriptional alterations in gene expression as well as changes in protein expression, thereby leading to massive metabolic reprogramming. This review seeks to provide a detailed account of various transcriptional regulations, proteomic changes, and metabolic reprogramming in various cancer models in response to three primary chemotherapeutic interventions, docetaxel, carboplatin, and doxorubicin. Discussing the molecular targets of some of these regulatory events and highlighting their contribution in sensitivity to chemotherapy will provide insights into drug resistance mechanisms and uncover novel perspectives in cancer treatment.
Collapse
Affiliation(s)
- Animesh Kar
- Regional Centre for Biotechnology, NCR Biotech Science Cluster, 3rd Milestone Faridabad-Gurgaon Expressway, Faridabad-121001, Haryana, India
| | - Shivam Agarwal
- Amity Institute of Integrative Sciences and Health, Amity University Haryana, Panchgaon, Manesar, Gurgaon-122413, Haryana, India
| | - Agrata Singh
- Amity Institute of Integrative Sciences and Health, Amity University Haryana, Panchgaon, Manesar, Gurgaon-122413, Haryana, India
| | - Avinash Bajaj
- Regional Centre for Biotechnology, NCR Biotech Science Cluster, 3rd Milestone Faridabad-Gurgaon Expressway, Faridabad-121001, Haryana, India
| | - Ujjaini Dasgupta
- Amity Institute of Integrative Sciences and Health, Amity University Haryana, Panchgaon, Manesar, Gurgaon-122413, Haryana, India.
| |
Collapse
|
4
|
Manzoor HB, Asare-Werehene M, Pereira SD, Satyamoorthy K, Tsang BK. The regulation of plasma gelsolin by DNA methylation in ovarian cancer chemo-resistance. J Ovarian Res 2024; 17:15. [PMID: 38216951 PMCID: PMC10785480 DOI: 10.1186/s13048-023-01332-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2023] [Accepted: 12/22/2023] [Indexed: 01/14/2024] Open
Abstract
BACKGROUND Ovarian cancer (OVCA) is the most lethal gynecologic cancer and chemoresistance remains a major hurdle to successful therapy and survival of OVCA patients. Plasma gelsolin (pGSN) is highly expressed in chemoresistant OVCA compared with their chemosensitive counterparts, although the mechanism underlying the differential expression is not known. Also, its overexpression significantly correlates with shortened survival of OVCA patients. In this study, we investigated the methylation role of Ten eleven translocation isoform-1 (TET1) in the regulation of differential pGSN expression and chemosensitivity in OVCA cells. METHODS Chemosensitive and resistant OVCA cell lines of different histological subtypes were used in this study to measure pGSN and TET1 mRNA abundance (qPCR) as well as protein contents (Western blotting). To investigate the role of DNA methylation specifically in pGSN regulation and pGSN-induced chemoresistance, DNMTs and TETs were pharmacologically inhibited in sensitive and resistant OVCA cells using specific inhibitors. DNA methylation was quantified using EpiTYPER MassARRAY system. Gain-and-loss-of-function assays were used to investigate the relationship between TET1 and pGSN in OVCA chemoresponsiveness. RESULTS We observed differential protein and mRNA expressions of pGSN and TET1 between sensitive and resistant OVCA cells and cisplatin reduced their expression in sensitive but not in resistant cells. We observed hypomethylation at pGSN promoter upstream region in resistant cells compared to sensitive cells. Pharmacological inhibition of DNMTs increased pGSN protein levels in sensitive OVCA cells and decreased their responsiveness to cisplatin, however we did not observe any difference in methylation level at pGSN promoter region. TETs inhibition resulted in hypermethylation at multiple CpG sites and decreased pGSN protein level in resistant OVCA cells which was also associated with enhanced response to cisplatin, findings that suggested the methylation role of TETs in the regulation of pGSN expression in OVCA cells. Further, we found that TET1 is inversely related to pGSN but positively related to chemoresponsiveness of OVCA cells. CONCLUSION Our findings broaden our knowledge about the epigenetic regulation of pGSN in OVCA chemoresistance and reveal a novel potential target to re-sensitize resistant OVCA cells. This may provide a future therapeutic strategy to improve the overall OVCA patient survival.
Collapse
Affiliation(s)
- Hafiza Bushra Manzoor
- Chronic Disease Program, Ottawa Hospital Research Institute, Ottawa, ON, K1H 8L6, Canada
- Department of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa, Ottawa, ON, K1H 8M5, Canada
| | - Meshach Asare-Werehene
- Chronic Disease Program, Ottawa Hospital Research Institute, Ottawa, ON, K1H 8L6, Canada
- Department of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa, Ottawa, ON, K1H 8M5, Canada
- Department of Obstetrics & Gynecology, & The Centre for Infection, Immunity and Inflammation (CI3), Faculty of Medicine & Interdisciplinary School of Health Sciences, Faculty of Health Sciences, University of Ottawa, Ottawa, ON, K1H 8L1, Canada
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada
| | - Satyajit Dey Pereira
- Department of Cell and Molecular Biology, Manipal School of Life Sciences, Manipal Academy of Higher Education, Manipal, Karnataka, 576104, India
| | - Kapaettu Satyamoorthy
- Shri Dharmasthala Manjunatheshwara University, Manjushree Block, Manjushree Nagar Sattur, Dharwad, Karnataka, 580 009, India
| | - Benjamin K Tsang
- Chronic Disease Program, Ottawa Hospital Research Institute, Ottawa, ON, K1H 8L6, Canada.
- Department of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa, Ottawa, ON, K1H 8M5, Canada.
- Department of Obstetrics & Gynecology, & The Centre for Infection, Immunity and Inflammation (CI3), Faculty of Medicine & Interdisciplinary School of Health Sciences, Faculty of Health Sciences, University of Ottawa, Ottawa, ON, K1H 8L1, Canada.
| |
Collapse
|
5
|
Tümerdem BŞ, Akbaba TH, Batu ED, Akkaya-Ulum YZ, Mutlu P, Ozen S, Balci-Peynircioğlu B. Drug metabolism and inflammation related distinct miRNA signature of colchicine resistant familial Mediterranean fever patients. Int Immunopharmacol 2023; 124:111011. [PMID: 37844462 DOI: 10.1016/j.intimp.2023.111011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2023] [Revised: 09/14/2023] [Accepted: 09/27/2023] [Indexed: 10/18/2023]
Abstract
OBJECTIVE Colchicine is the primary treatment for familial Mediterranean fever (FMF). Although colchicine is safe and effective in FMF patients, around 5-10% of patients show resistance to the drug. This study investigates the possibility of a link between colchicine resistance and the distinct miRNA profiles in colchicine resistant FMF patients. METHODS Differentially expressed miRNAs in colchicine resistant FMF patients were detected by Affymetrix 4.0 miRNA array analysis. These miRNAs were then categorized based on the role of their target genes in drug metabolism and inflammation related pathways. qRT-PCR was used to validate candidate miRNAs selected by Enrichr, a gene enrichment analysis system based on the relevance of possible target genes in drug metabolism pathways. Expression levels of these miRNAs' potential target genes were investigated by qRT-PCR. Then, a colchicine resistant hepatoblastoma cell line (HEPG2) was established, and the differentially expressed miRNAs and genes identified in patients were also analyzed in this colchicine-resistant cell line. RESULTS 25 differentially expressed miRNAs were detected in colchicine resistant FMF patients. miR-183-5p, miR-15b-5p, miR-505-5p, and miR-125a-5p were identified to be associated with drug resistance and inflammatory pathways and thus chosen for further validation. miR-183-5p, miR-15b-5p, miR-505-5p miRNAs showed significantly differential expression in qRT-PCR. NFKB1, NR3C1, PPARα - drug absorption, distribution, metabolism, and excretion (ADME) genes were predicted to be targeted by these miRNAs. Among these targets, NFKB1 and NR3C1 were differentially over expressed in colchicine resistant FMF patients. These findings were validated in the colchicine resistant hepatoblastoma cell line (HEPG2). CONCLUSION This is the first study evaluating the role of miRNAs in colchicine resistant patients with FMF. Their differential expression may result in resistance to standard colchicine treatment by affecting the expression of genes that take place in drug absorption, distribution, metabolism, and excretion (ADME) or nuclear receptors that regulate ADME genes, thus potentially playing a role in both drug metabolism and inflammation.
Collapse
Affiliation(s)
- Bilgesu Şafak Tümerdem
- Department of Medical Biology, Faculty of Medicine, Hacettepe University, Ankara, Turkey
| | - Tayfun Hilmi Akbaba
- Department of Medical Biology, Faculty of Medicine, Hacettepe University, Ankara, Turkey
| | - Ezgi Deniz Batu
- Division of Rheumatology, Department of Pediatrics, Faculty of Medicine, Hacettepe University, Ankara, Turkey
| | - Yeliz Z Akkaya-Ulum
- Department of Medical Biology, Faculty of Medicine, Hacettepe University, Ankara, Turkey
| | - Pelin Mutlu
- Institute of Biotechnology, Ankara University, Ankara, Turkey
| | - Seza Ozen
- Division of Rheumatology, Department of Pediatrics, Faculty of Medicine, Hacettepe University, Ankara, Turkey
| | | |
Collapse
|
6
|
Macieja A, Gulbas I, Popławski T. DNA Double-Strand Break Repair Inhibitors: YU238259, A12B4C3 and DDRI-18 Overcome the Cisplatin Resistance in Human Ovarian Cancer Cells, but Not under Hypoxia Conditions. Curr Issues Mol Biol 2023; 45:7915-7932. [PMID: 37886943 PMCID: PMC10605129 DOI: 10.3390/cimb45100500] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2023] [Revised: 09/25/2023] [Accepted: 09/26/2023] [Indexed: 10/28/2023] Open
Abstract
Cisplatin (CDDP) is the cornerstone of standard treatment for ovarian cancer. However, the resistance of ovarian cancer cells to CDDP leads to an inevitable recurrence. One of the strategies to overcome resistance to CDDP is the combined treatment of ovarian cancer with CDDP and etoposide (VP-16), although this strategy is not always effective. This article presents a new approach to sensitize CDDP-resistant human ovarian carcinoma cells to combined treatment with CDDP and VP-16. To replicate the tumor conditions of cancers, we performed analysis under hypoxia conditions. Since CDDP and VP-16 induce DNA double-strand breaks (DSB), we introduce DSB repair inhibitors to the treatment scheme. We used novel HRR and NHEJ inhibitors: YU238259 inhibits the HRR pathway, and DDRI-18 and A12B4C3 act as NHEJ inhibitors. All inhibitors enhanced the therapeutic effect of the CDDP/VP-16 treatment scheme and allowed a decrease in the effective dose of CDDP/VP16. Inhibition of HRR or NHEJ decreased survival and increased DNA damage level, increased the amount of γ-H2AX foci, and caused an increase in apoptotic fraction after treatment with CDDP/VP16. Furthermore, delayed repair of DSBs was detected in HRR- or NHEJ-inhibited cells. This favorable outcome was altered under hypoxia, during which alternation at the transcriptome level of the transcriptome in cells cultured under hypoxia compared to aerobic conditions. These changes suggest that it is likely that other than classical DSB repair systems are activated in cancer cells during hypoxia. Our study suggests that the introduction of DSB inhibitors may improve the effectiveness of commonly used ovarian cancer treatment, and HRR, as well as NHEJ, is an attractive therapeutic target for overcoming the resistance to CDDP resistance of ovarian cancer cells. However, a hypoxia-mediated decrease in response to our scheme of treatment was observed.
Collapse
Affiliation(s)
- Anna Macieja
- Department of Microbiology and Pharmaceutical Biochemistry, Medical University of Lodz, Mazowiecka 5, 92-215 Lodz, Poland;
| | - Izabela Gulbas
- Department of Immunology and Allergy, Medical University of Lodz, Pomorska 251, 92-213 Lodz, Poland;
| | - Tomasz Popławski
- Department of Microbiology and Pharmaceutical Biochemistry, Medical University of Lodz, Mazowiecka 5, 92-215 Lodz, Poland;
| |
Collapse
|
7
|
Qin T, Fan J, Lu F, Zhang L, Liu C, Xiong Q, Zhao Y, Chen G, Sun C. Harnessing preclinical models for the interrogation of ovarian cancer. J Exp Clin Cancer Res 2022; 41:277. [PMID: 36114548 PMCID: PMC9479310 DOI: 10.1186/s13046-022-02486-z] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2022] [Accepted: 09/05/2022] [Indexed: 12/24/2022] Open
Abstract
Ovarian cancer (OC) is a heterogeneous malignancy with various etiology, histopathology, and biological feature. Despite accumulating understanding of OC in the post-genomic era, the preclinical knowledge still undergoes limited translation from bench to beside, and the prognosis of ovarian cancer has remained dismal over the past 30 years. Henceforth, reliable preclinical model systems are warranted to bridge the gap between laboratory experiments and clinical practice. In this review, we discuss the status quo of ovarian cancer preclinical models which includes conventional cell line models, patient-derived xenografts (PDXs), patient-derived organoids (PDOs), patient-derived explants (PDEs), and genetically engineered mouse models (GEMMs). Each model has its own strengths and drawbacks. We focus on the potentials and challenges of using these valuable tools, either alone or in combination, to interrogate critical issues with OC.
Collapse
|
8
|
Dysfunctional activity of classical DNA end-joining renders acquired resistance to carboplatin in human ovarian cancer cells. Cancer Lett 2021; 520:267-280. [PMID: 34375710 DOI: 10.1016/j.canlet.2021.08.003] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2021] [Revised: 06/13/2021] [Accepted: 08/02/2021] [Indexed: 12/13/2022]
Abstract
Ovarian cancer is the deadliest gynecological malignancy worldwide. Although chemotherapy is required as the most standard treatment strategy for ovarian cancer, the survival rates are very low, largely because of high incidence of recurrence due to resistance to conventional surgery and genotoxic chemotherapies. Carboplatin-resistant ovarian cancer cells were generated by continuous treatment over six months. Carboplatin-resistance induced morphological alterations and promoted the rates of proliferation and migration of SKOV3 compared to the parental cells. Interestingly, carboplatin-resistant SKOV3 showed the high levels of γH2AX foci formed at the basal level, and the levels of γH2AX foci remained even after the recovery time, suggesting that the DNA damage response and repair machinery were severely attenuated by carboplatin-resistance. Surprisingly, the expression levels of XRCC4, a critical factor in non-homologous end joining (NHEJ) DNA repair, were significantly decreased in carboplatin-resistant SKOV3 compared with those in non-resistant controls. Furthermore, restoration of NHEJ in carboplatin-resistant SKOV3 by suppression of ABCB1 and/or AR re-sensitized carboplatin-resistant cells to genotoxic stress and reduced their proliferation ability. Our findings suggest that attenuation of the NHEJ DNA repair machinery mediated by resistance to genotoxic stress might be a critical cause of chemoresistance in patients with ovarian cancer.
Collapse
|
9
|
Southern A, El-Bahrawy M. Advances in understanding the molecular pathology of gynecological malignancies: the role and potential of RNA sequencing. Int J Gynecol Cancer 2021; 31:1159-1164. [PMID: 34016704 DOI: 10.1136/ijgc-2021-002509] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2021] [Revised: 05/04/2021] [Accepted: 05/07/2021] [Indexed: 11/03/2022] Open
Abstract
For many years technological limitations restricted the progress of identifying the underlying genetic causes of gynecologicalcancers. However, during the past decade, high-throughput next-generation sequencing technologies have revolutionized cancer research. RNA sequencing has arisen as a very useful technique in expanding our understanding of genome changes in cancer. Cancer is characterized by the accumulation of genetic alterations affecting genes, including substitutions, insertions, deletions, translocations, gene fusions, and alternative splicing. If these aberrant genes become transcribed, aberrations can be detected by RNA sequencing, which will also provide information on the transcript abundance revealing the expression levels of the aberrant genes. RNA sequencing is considered the technique of choice when studying gene expression and identifying new RNA species. This is due to the quantitative and qualitative improvement that it has brought to transcriptome analysis, offering a resolution that allows research into different layers of transcriptome complexity. It has also been successful in identifying biomarkers, fusion genes, tumor suppressors, and uncovering new targets responsible for drug resistance in gynecological cancers. To illustrate that we here review the role of RNA sequencing in studies that enhanced our understanding of the molecular pathology of gynecological cancers.
Collapse
Affiliation(s)
- Alba Southern
- Surgery and Cancer, Imperial College London, London, UK
| | - Mona El-Bahrawy
- Metabolism, Digestion and Reproduction, Imperial College London, London, UK .,Pathology, Alexandria University Faculty of Medicine, Alexandria, Egypt
| |
Collapse
|
10
|
Abedi M, Abolmaali SS, Heidari R, Mohammadi Samani S, Tamaddon AM. Hierarchical mesoporous zinc-imidazole dicarboxylic acid MOFs: Surfactant-directed synthesis, pH-responsive degradation, and drug delivery. Int J Pharm 2021; 602:120685. [PMID: 33964340 DOI: 10.1016/j.ijpharm.2021.120685] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2021] [Revised: 04/30/2021] [Accepted: 05/03/2021] [Indexed: 01/22/2023]
Abstract
The surfactant template-directed solvothermal method was applied in the synthesis of hierarchical mesoporous zinc-imidazolate derivative metal-organic framework (mesoMOF), which was then utilized for active loading of cisplatin (cis-Pt). To fabricate mesoMOF, various amounts of the surfactant (cetyltrimethylammonium bromide: 0.1-0.3 g) and linker (citric acid: 0.05-0.15 g) were added to the reaction mixture, which resulted in different particle sizes and morphologies. MesoMOF quality attributes such as Specific surface area (SSA), total porous volume, and Barrett-Joyner-Halenda (BJH) pore diameter were also determined. At the optimum reaction condition, mesoMOF with a high surface area (1859 m2/g), pore diameter (14.13 nm) and total pore volume (0.314 cm3/g) was attained. In the next step, cis-Pt was actively loaded in the mesoMOF with a high loading capacity (28% w/w), which was remarkably superior to the microporous MOF. Interestingly, in mildly acidic pH (5.5), mesoMOF underwent degradation, resulting in a rapid release of cis-Pt. Cell viability and apoptosis induction assays confirmed the superiority of the cis-Pt loaded mesoMOF over free drug in a resistant ovarian tumor cell line (A2780cp). Altogether, due to their tunable size and morphology, pH-responsiveness, and acceptable tolerability in mice, the mesoMOFs can be regarded as an anti-cancer drug delivery system.
Collapse
Affiliation(s)
- Mehdi Abedi
- Department of Pharmaceutical Nanotechnology, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran
| | - Samira Sadat Abolmaali
- Department of Pharmaceutical Nanotechnology, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran; Center for Nanotechnology in Drug Delivery, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.
| | - Reza Heidari
- Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
| | - Soliman Mohammadi Samani
- Center for Nanotechnology in Drug Delivery, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran; Department of Pharmaceutics, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.
| | - Ali Mohammad Tamaddon
- Department of Pharmaceutical Nanotechnology, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran; Center for Nanotechnology in Drug Delivery, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.
| |
Collapse
|
11
|
Bolitho EM, Bridgewater HE, Needham RJ, Coverdale JPC, Quinn PD, Sanchez-Cano C, Sadler PJ. Elemental mapping of half-sandwich azopyridine osmium arene complexes in cancer cells. Inorg Chem Front 2021. [DOI: 10.1039/d1qi00512j] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Abstract
Nanofocused synchrotron X-ray fluorescence and inductively coupled plasma-mass spectrometry provide insights into time-dependent ligand exchange reactions of organo-osmium anticancer complexes in cancer cells. Created with Biorender.com.
Collapse
Affiliation(s)
| | | | | | | | | | - Carlos Sanchez-Cano
- Center for Cooperative Research in Biomaterials (CIC biomaGUNE)
- Basque Research and Technology Alliance (BRTA)
- San Sebastián
- Spain
| | | |
Collapse
|
12
|
Studer V, Anghel N, Desiatkina O, Felder T, Boubaker G, Amdouni Y, Ramseier J, Hungerbühler M, Kempf C, Heverhagen JT, Hemphill A, Ruprecht N, Furrer J, Păunescu E. Conjugates Containing Two and Three Trithiolato-Bridged Dinuclear Ruthenium(II)-Arene Units as In Vitro Antiparasitic and Anticancer Agents. Pharmaceuticals (Basel) 2020; 13:E471. [PMID: 33339451 PMCID: PMC7767221 DOI: 10.3390/ph13120471] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2020] [Revised: 12/10/2020] [Accepted: 12/11/2020] [Indexed: 12/15/2022] Open
Abstract
The synthesis, characterization, and in vitro antiparasitic and anticancer activity evaluation of new conjugates containing two and three dinuclear trithiolato-bridged ruthenium(II)-arene units are presented. Antiparasitic activity was evaluated using transgenic Toxoplasmagondii tachyzoites constitutively expressing β-galactosidase grown in human foreskin fibroblasts (HFF). The compounds inhibited T.gondii proliferation with IC50 values ranging from 90 to 539 nM, and seven derivatives displayed IC50 values lower than the reference compound pyrimethamine, which is currently used for treatment of toxoplasmosis. Overall, compound flexibility and size impacted on the anti-Toxoplasma activity. The anticancer activity of 14 compounds was assessed against cancer cell lines A2780, A2780cisR (human ovarian cisplatin sensitive and resistant), A24, (D-)A24cisPt8.0 (human lung adenocarcinoma cells wild type and cisPt resistant subline). The compounds displayed IC50 values ranging from 23 to 650 nM. In A2780cisR, A24 and (D-)A24cisPt8.0 cells, all compounds were considerably more cytotoxic than cisplatin, with IC50 values lower by two orders of magnitude. Irrespective of the nature of the connectors (alkyl/aryl) or the numbers of the di-ruthenium units (two/three), ester conjugates 6-10 and 20 exhibited similar antiproliferative profiles, and were more cytotoxic than amide analogues 11-14, 23, and 24. Polynuclear conjugates with multiple trithiolato-bridged di-ruthenium(II)-arene moieties deserve further investigation.
Collapse
Affiliation(s)
- Valentin Studer
- Department of Chemistry and Biochemistry, University of Bern, Freiestrasse 3, CH-3012 Bern, Switzerland; (V.S.); (O.D.); (T.F.)
| | - Nicoleta Anghel
- Vetsuisse Faculty, Institute of Parasitology, University of Bern, Länggassstrasse 122, CH-3012 Bern, Switzerland; (N.A.); (G.B.); (Y.A.); (J.R.)
| | - Oksana Desiatkina
- Department of Chemistry and Biochemistry, University of Bern, Freiestrasse 3, CH-3012 Bern, Switzerland; (V.S.); (O.D.); (T.F.)
| | - Timo Felder
- Department of Chemistry and Biochemistry, University of Bern, Freiestrasse 3, CH-3012 Bern, Switzerland; (V.S.); (O.D.); (T.F.)
| | - Ghalia Boubaker
- Vetsuisse Faculty, Institute of Parasitology, University of Bern, Länggassstrasse 122, CH-3012 Bern, Switzerland; (N.A.); (G.B.); (Y.A.); (J.R.)
| | - Yosra Amdouni
- Vetsuisse Faculty, Institute of Parasitology, University of Bern, Länggassstrasse 122, CH-3012 Bern, Switzerland; (N.A.); (G.B.); (Y.A.); (J.R.)
- Laboratoire de Parasitologie, Institution de la Recherche et de l’Enseignement Supérieur Agricoles, École Nationale de Médecine Vétérinaire de Sidi Thabet, University of Manouba, Sidi Thabet 2020, Tunisia
| | - Jessica Ramseier
- Vetsuisse Faculty, Institute of Parasitology, University of Bern, Länggassstrasse 122, CH-3012 Bern, Switzerland; (N.A.); (G.B.); (Y.A.); (J.R.)
| | - Martin Hungerbühler
- Department of BioMedical Research, Experimental Radiology, University of Bern, CH-3008 Bern, Switzerland; (M.H.); (C.K.); (J.T.H.)
- Department of Diagnostic, Interventional and Pediatric Radiology, Bern University Hospital, University of Bern, CH-3010 Bern, Switzerland
| | - Christoph Kempf
- Department of BioMedical Research, Experimental Radiology, University of Bern, CH-3008 Bern, Switzerland; (M.H.); (C.K.); (J.T.H.)
- Department of Diagnostic, Interventional and Pediatric Radiology, Bern University Hospital, University of Bern, CH-3010 Bern, Switzerland
| | - Johannes Thomas Heverhagen
- Department of BioMedical Research, Experimental Radiology, University of Bern, CH-3008 Bern, Switzerland; (M.H.); (C.K.); (J.T.H.)
- Department of Diagnostic, Interventional and Pediatric Radiology, Bern University Hospital, University of Bern, CH-3010 Bern, Switzerland
| | - Andrew Hemphill
- Vetsuisse Faculty, Institute of Parasitology, University of Bern, Länggassstrasse 122, CH-3012 Bern, Switzerland; (N.A.); (G.B.); (Y.A.); (J.R.)
| | - Nico Ruprecht
- Department of BioMedical Research, Experimental Radiology, University of Bern, CH-3008 Bern, Switzerland; (M.H.); (C.K.); (J.T.H.)
- Department of Diagnostic, Interventional and Pediatric Radiology, Bern University Hospital, University of Bern, CH-3010 Bern, Switzerland
| | - Julien Furrer
- Department of Chemistry and Biochemistry, University of Bern, Freiestrasse 3, CH-3012 Bern, Switzerland; (V.S.); (O.D.); (T.F.)
| | - Emilia Păunescu
- Department of Chemistry and Biochemistry, University of Bern, Freiestrasse 3, CH-3012 Bern, Switzerland; (V.S.); (O.D.); (T.F.)
| |
Collapse
|
13
|
Santana-Rivera Y, Rabelo-Fernández RJ, Quiñones-Díaz BI, Grafals-Ruíz N, Santiago-Sánchez G, Lozada-Delgado EL, Echevarría-Vargas IM, Apiz J, Soto D, Rosado A, Meléndez L, Valiyeva F, Vivas-Mejía PE. Reduced expression of enolase-1 correlates with high intracellular glucose levels and increased senescence in cisplatin-resistant ovarian cancer cells. Am J Transl Res 2020; 12:1275-1292. [PMID: 32355541 PMCID: PMC7191177] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2020] [Accepted: 03/10/2020] [Indexed: 06/11/2023]
Abstract
Despite good responses to first-line treatment with platinum-based combination chemotherapy, most ovarian cancer patients will relapse and eventually develop a platinum-resistant disease with a poor overall prognosis. The molecular events leading to the cisplatin resistance of ovarian cancer cells are not fully understood. Here, we performed a proteomic analysis to identify protein candidates deregulated in a cisplatin-resistant ovarian cancer cell line (A2780CP20) in comparison to their sensitive counterpart (A2780). Forty-eight proteins were differentially abundant in A2780CP20, as compared with A2780, cells. Enolase-1 (ENO1) was significantly decreased in cisplatin-resistant ovarian cancer cells. Western blots and RT-PCR confirmed our findings. Ectopic ENO1 expression increased the sensitivity of ovarian cancer cells to cisplatin treatment. In contrast, small-interfering (siRNA)-based ENO1 silencing in A2780 cells reduced the sensitivity of these cells to cisplatin treatment. Whereas glucose consumption was lower, intracellular levels were higher in cisplatin-resistant ovarian cancer cells as compared with their cisplatin-sensitive counterparts. Senescence-associated β-galactosidase (β-Gal) levels were higher in cisplatin-resistant ovarian cancer cells as compared with cisplatin-sensitive ovarian cancer cells. β-Gal levels were decreased in ENO1 overexpressed clones. Protein levels of the cell cycle regulators and senescence markers p21 and p53 showed opposite expression patterns in cisplatin-resistant compared with cisplatin sensitive cells. Our studies suggest that decreased expression of ENO1 promotes glucose accumulation, induces senescence, and leads to cisplatin resistance of ovarian cancer cells.
Collapse
Affiliation(s)
- Yasmarie Santana-Rivera
- Department of Interdisciplinary Sciences, University of Puerto Rico, Rio Piedras CampusSan Juan 00927, Puerto Rico
- Comprehensive Cancer Center, University of Puerto Rico, Medical Sciences CampusSan Juan 00935, Puerto Rico
| | - Robert J Rabelo-Fernández
- Department of Biology, University of Puerto Rico, Rio Piedras CampusSan Juan 00927, Puerto Rico
- Comprehensive Cancer Center, University of Puerto Rico, Medical Sciences CampusSan Juan 00935, Puerto Rico
| | - Blanca I Quiñones-Díaz
- Department of Biochemistry, University of Puerto Rico, Medical Sciences CampusSan Juan 00935, Puerto Rico
- Comprehensive Cancer Center, University of Puerto Rico, Medical Sciences CampusSan Juan 00935, Puerto Rico
| | - Nilmary Grafals-Ruíz
- Department of Physiology, University of Puerto Rico, Medical Sciences CampusSan Juan 00935, Puerto Rico
- Comprehensive Cancer Center, University of Puerto Rico, Medical Sciences CampusSan Juan 00935, Puerto Rico
| | - Ginette Santiago-Sánchez
- Department of Biochemistry, University of Puerto Rico, Medical Sciences CampusSan Juan 00935, Puerto Rico
- Comprehensive Cancer Center, University of Puerto Rico, Medical Sciences CampusSan Juan 00935, Puerto Rico
| | - Eunice L Lozada-Delgado
- Department of Biology, University of Puerto Rico, Rio Piedras CampusSan Juan 00927, Puerto Rico
- Comprehensive Cancer Center, University of Puerto Rico, Medical Sciences CampusSan Juan 00935, Puerto Rico
| | - Ileabett M Echevarría-Vargas
- Department of Biochemistry, University of Puerto Rico, Medical Sciences CampusSan Juan 00935, Puerto Rico
- Comprehensive Cancer Center, University of Puerto Rico, Medical Sciences CampusSan Juan 00935, Puerto Rico
| | - Juan Apiz
- Comprehensive Cancer Center, University of Puerto Rico, Medical Sciences CampusSan Juan 00935, Puerto Rico
- Department of Biology, University of Puerto Rico, Cayey CampusCayey 00736, Puerto Rico
| | - Daniel Soto
- Department of Biology, University of Puerto Rico, Rio Piedras CampusSan Juan 00927, Puerto Rico
- Comprehensive Cancer Center, University of Puerto Rico, Medical Sciences CampusSan Juan 00935, Puerto Rico
| | - Andrea Rosado
- Department of Interdisciplinary Sciences, University of Puerto Rico, Rio Piedras CampusSan Juan 00927, Puerto Rico
- Comprehensive Cancer Center, University of Puerto Rico, Medical Sciences CampusSan Juan 00935, Puerto Rico
| | - Loyda Meléndez
- Department of Microbiology and Medical Zoology, University of Puerto Rico, Medical Sciences CampusSan Juan 00935, Puerto Rico
- Comprehensive Cancer Center, University of Puerto Rico, Medical Sciences CampusSan Juan 00935, Puerto Rico
| | - Fatima Valiyeva
- Comprehensive Cancer Center, University of Puerto Rico, Medical Sciences CampusSan Juan 00935, Puerto Rico
| | - Pablo E Vivas-Mejía
- Department of Biochemistry, University of Puerto Rico, Medical Sciences CampusSan Juan 00935, Puerto Rico
- Comprehensive Cancer Center, University of Puerto Rico, Medical Sciences CampusSan Juan 00935, Puerto Rico
| |
Collapse
|
14
|
Mora-Lagos B, Cartas-Espinel I, Riquelme I, Parker AC, Piccolo SR, Viscarra T, Reyes ME, Zanella L, Buchegger K, Ili C, Brebi P. Functional and transcriptomic characterization of cisplatin-resistant AGS and MKN-28 gastric cancer cell lines. PLoS One 2020; 15:e0228331. [PMID: 31990955 PMCID: PMC6986722 DOI: 10.1371/journal.pone.0228331] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2019] [Accepted: 01/13/2020] [Indexed: 02/06/2023] Open
Abstract
Gastric cancer (GC) is a significant cancer-related cause of death worldwide. The most used chemotherapeutic regimen in GC is based on platinum drugs such as cisplatin (CDDP). However, CDDP resistance reduces advanced GC survival. In vitro drug-resistant cell model would help in the understanding of molecular mechanisms underlying this drug-resistance phenomenon. The aim of this study was to characterize new models of CDDP-resistant GC cell lines (AGS R-CDDP and MKN-28 R-CDDP) obtained through a stepwise increasing drug doses method, in order to understand the molecular mechanisms underlying chemoresistance as well as identify new therapeutic targets for the treatment of GC. Cell viability assays, cell death assays and the expression of resistance molecular markers confirmed that AGS R-CDDP and MKN-28 R-CDDP are reliable CDDP-resistant models. RNA-seq and bioinformatics analyses identified a total of 189 DEGs, including 178 up-regulated genes and 11 down-regulated genes, associated mainly to molecular functions involved in CDDP-resistance. DEGs were enriched in 23 metabolic pathways, among which the most enriched was the inflammation mediated by chemokine and cytokine signaling pathway. Finally, the higher mRNA expression of SERPINA1, BTC and CCL5, three up-regulated DEGs associated to CDDP resistance found by RNA-seq analysis was confirmed. In summary, this study showed that AGS R-CDDP and MKN-28 R-CDDP are reliable models of CDDP resistance because resemble many of resistant phenotype in GC, being also useful to assess potential therapeutic targets for the treatment of gastric cancers resistant to CDDP. In addition, we identified several DEGs associated with molecular functions such as binding, catalytic activity, transcription regulator activity and transporter activity, as well as signaling pathways associated with inflammation process, which could be involved in the development of CDDP resistance in GC. Further studies are necessary to clarify the role of inflammatory processes in GC resistant to CDDP and these models could be useful for these purposes.
Collapse
Affiliation(s)
- Barbara Mora-Lagos
- Laboratory of Integrative Biology (LIBi), Scientific and Technological Bioresource Nucleus- Center for Excellence in Translational Medicine (BIOREN-CEMT), Universidad de La Frontera, Temuco, Chile
- Dirección de Investigación, Vicerrectoría de Investigación y Postgrado, Universidad Autónoma de Chile, Temuco, Chile
| | - Irene Cartas-Espinel
- Laboratory of Integrative Biology (LIBi), Scientific and Technological Bioresource Nucleus- Center for Excellence in Translational Medicine (BIOREN-CEMT), Universidad de La Frontera, Temuco, Chile
| | - Ismael Riquelme
- Instituto de Ciencias Biomédicas, Facultad de Ciencias de la Salud, Universidad Autónoma de Chile, Temuco, Chile
| | - Alyssa C. Parker
- Department of Biology, Brigham Young University, Provo, Utah, United States of America
| | - Stephen R. Piccolo
- Department of Biology, Brigham Young University, Provo, Utah, United States of America
| | - Tamara Viscarra
- Laboratory of Integrative Biology (LIBi), Scientific and Technological Bioresource Nucleus- Center for Excellence in Translational Medicine (BIOREN-CEMT), Universidad de La Frontera, Temuco, Chile
| | - María Elena Reyes
- Laboratory of Integrative Biology (LIBi), Scientific and Technological Bioresource Nucleus- Center for Excellence in Translational Medicine (BIOREN-CEMT), Universidad de La Frontera, Temuco, Chile
| | - Louise Zanella
- Laboratory of Integrative Biology (LIBi), Scientific and Technological Bioresource Nucleus- Center for Excellence in Translational Medicine (BIOREN-CEMT), Universidad de La Frontera, Temuco, Chile
| | - Kurt Buchegger
- Laboratory of Integrative Biology (LIBi), Scientific and Technological Bioresource Nucleus- Center for Excellence in Translational Medicine (BIOREN-CEMT), Universidad de La Frontera, Temuco, Chile
- Department of Basic Sciences, School of Medicine, Universidad de La Frontera, Temuco, Chile
| | - Carmen Ili
- Laboratory of Integrative Biology (LIBi), Scientific and Technological Bioresource Nucleus- Center for Excellence in Translational Medicine (BIOREN-CEMT), Universidad de La Frontera, Temuco, Chile
- * E-mail: (CI); (PB)
| | - Priscilla Brebi
- Laboratory of Integrative Biology (LIBi), Scientific and Technological Bioresource Nucleus- Center for Excellence in Translational Medicine (BIOREN-CEMT), Universidad de La Frontera, Temuco, Chile
- * E-mail: (CI); (PB)
| |
Collapse
|